European Heart Journal Advance Access originally published online on November 15, 2006
European Heart Journal 2006 27(23):2815-2822; doi:10.1093/eurheartj/ehl385
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cause of death with bare metal and sirolimus-eluting stents
1 Division of Cardiovascular Diseases, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
2 Center for Interventional Vascular Therapy, Columbia University Medical Center, New York, NY, USA
3 Hamburg University Cardiovascular Center, Hamburg, Germany
4 Institut Cardiovasculaire Paris Sud, Institute Hospitalier Jacques Cartier, Massy, France
5 Cardiac Catheterization Laboratories, Division of Cardiology, Hôpital du Sacré-Coeur de Montréal, Montréal, Québec, Canada
Received 27 July 2006; revised 9 October 2006; accepted 31 October 2006; online publish-ahead-of-print 15 November 2006.
* Corresponding author. Consultant, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
See page 2737 for the editorial comment on this article (doi:10.1093/eurheartj/ehl378)
Aims Although drug-eluting stents have assumed a dominant role in interventional cardiology, concern has been raised about the potential for long-term adverse outcomes, including death. The aim of the present study was to compare the incidence and cause of death between patients who received sirolimus-eluting or bare metal stents.
Methods and results An integrated analysis was performed on 1748 patients enrolled in four prospective double-blind trials that randomly assigned patients to receive either a sirolimus-eluting or a bare metal stent for treatment of a single de novo coronary stenosis. During a mean follow-up of 2.6±0.6 years, 64 patients (3.7%) died. Total mortality was 3.2% among 870 bare metal stent patients and 4.1% among 878 sirolimus-eluting stent patients (P=0.37); there was no difference in cardiac mortality (1.4 vs. 1.3%; P=0.55) or causes of death between these two groups. The predominant cause of death was non-cardiac. Cardiac death was most frequently assigned owing to unwitnessed death. Death due to acute myocardial infarction, congestive heart failure, and stent thrombosis occurred infrequently.
Conclusion At a mean follow-up of 2.6 years in percutaneous coronary intervention patients, the predominant cause of death was non-cardiac. There was no significant difference in either the frequency or the cause of death with implantation of either sirolimus-eluting or bare metal stents.
Key Words: Cardiac death Drug-eluting stents Follow-up mortality
![]()
CiteULike
Connotea
Del.icio.us What's this?
Related articles in EHJ:
- Increased mortality after implantation of first generation drug-eluting stents: seeing the smoke, where is the fire?
- William C. Wijns and Mitchell W. Krucoff
EHJ 2006 27: 2737-2739.[Extract] [Full Text]
This article has been cited by other articles:
![]() |
D. Austin, K. G. Oldroyd, A. McConnachie, R. Slack, H. Eteiba, A. D. Flapan, K. P. Jennings, R. J. Northcote, A. C.H. Pell, I. R. Starkey, et al. Drug-Eluting Stents Versus Bare-Metal Stents for Off-Label Indications: A Propensity Score-Matched Outcome Study Circ Cardiovasc Intervent, August 1, 2008; 1(1): 45 - 52. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Brasselet, E. Durand, F. Addad, F. Vitry, G. Chatellier, C. Demerens, M. Lemitre, R. Garnotel, D. Urbain, P. Bruneval, et al. Effect of local heating on restenosis and in-stent neointimal hyperplasia in the atherosclerotic rabbit model: a dose-ranging study Eur. Heart J., February 1, 2008; 29(3): 402 - 412. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R Bennett Vascular pathology as a result of drug-eluting stents Heart, August 1, 2007; 93(8): 895 - 896. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. R. Holmes Jr, D. J. Kereiakes, W. K. Laskey, A. Colombo, S. G. Ellis, T. D. Henry, J. J. Popma, P. W.J.C. Serruys, T. Kimura, D. O. Williams, et al. Thrombosis and Drug-Eluting Stents: An Objective Appraisal J. Am. Coll. Cardiol., July 10, 2007; 50(2): 109 - 118. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Camenzind, P. G. Steg, and W. Wijns A Cause for Concern Circulation, March 20, 2007; 115(11): 1440 - 1455. [Full Text] [PDF] |
||||
![]() |
A. Kastrati, J. Mehilli, J. Pache, C. Kaiser, M. Valgimigli, H. Kelbaek, M. Menichelli, M. Sabate, M. J. Suttorp, D. Baumgart, et al. Analysis of 14 Trials Comparing Sirolimus-Eluting Stents with Bare-Metal Stents N. Engl. J. Med., March 8, 2007; 356(10): 1030 - 1039. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. G.L. Biondi-Zoccai, A. Abbate, M. Valgimigli, and P. Agostoni Keeping a high standard in quantitative analyses, meta-analyses, and systematic reviews Eur. Heart J., February 8, 2007; (2007) ehl502v1. [Full Text] [PDF] |
||||
![]() |
W. C. Wijns and M. W. Krucoff Increased mortality after implantation of first generation drug-eluting stents: seeing the smoke, where is the fire? Eur. Heart J., December 1, 2006; 27(23): 2737 - 2739. [Full Text] [PDF] |
||||





